A new era for treatment of drug-resistant tuberculosis

Neel R. Gandhi, James C.M. Brust, N. Sarita Shah

Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018
Journal Issue: October
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Neel R. Gandhi, James C.M. Brust, N. Sarita Shah. A new era for treatment of drug-resistant tuberculosis. Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Treatment of TB
Source: Eur Respir Mon 2012; 58: 154-166
Year: 2012

Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018

Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008

Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis
Source: Annual Congress 2009 - Priorities in tuberculosis research
Year: 2009

Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Source: Eur Respir J 2009; 33: 1085-1094
Year: 2009

Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017

Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen
Source: Eur Respir J, 52 (6) 1801528; 10.1183/13993003.01528-2018
Year: 2018

Treatment of drug-susceptible and drug-resistant tuberculosis
Source: Eur Respir Monogr 2018; 82: 152-178
Year: 2018

Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?
Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019
Year: 2020

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Source: Eur Respir J 2012; 39: 956-962
Year: 2012

Clinical and operational value of the extensively drug-resistant tuberculosis definition
Source: Eur Respir J 2007; 30: 623-626
Year: 2007

Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?
Source: Eur Respir J 2013; 42: 1449-1453
Year: 2013

Multidrug- and extensively drug-resistant tuberculosis: an emerging threat
Source: Eur Respir Rev 2009; 18: 195-197
Year: 2009

Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005

Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019

Management and treatment of multidrug-resistant tuberculosis
Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management
Year: 2019

Surgical treatment of multidrug-resistant tuberculosis (MDR TB)
Source: Eur Respir J 2003; 22: Suppl. 45, 523s
Year: 2003

The individual-tailored treatment regimens for multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012

Application of therapeutic pneumoperitoneum for multi-drug resistant cavitary TB in HIV – infected patients
Source: Eur Respir J 2004; 24: Suppl. 48, 650s
Year: 2004